Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026)
Codexis' (CDXS) quarterly Total Non-Current Liabilities came in at $84.8 million in Q1 2026, up 8.75% year-on-year from $78.0 million in Q1 2025, and down 11.61% quarter-over-quarter from $95.9 million in Q4 2025.
Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Codexis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $84.8 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 8.75% year-over-year to $84.8 million in Q1 2026; TTM through Mar 2026 was $84.8 million, a 8.75% increase from a year earlier, with the FY2025 full-year figure at $95.9 million, up 18.72% from the prior year.
- Total Non-Current Liabilities slipped to $84.8 million in Q1 2026 per CDXS's latest filing, from $95.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $104.2 million in Q4 2022 and bottomed at $48.7 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $79.8 million (2022), against an average of $78.4 million.
- Across the five-year window, Total Non-Current Liabilities plunged 53.26% in 2023 and soared 65.9% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $104.2 million in 2022, then plunged by 53.26% to $48.7 million in 2023, then surged by 65.9% to $80.8 million in 2024, then rose by 18.72% to $95.9 million in 2025, then retreated by 11.61% to $84.8 million in 2026.
- Per Business Quant, the three latest CDXS Total Non-Current Liabilities figures stand at $84.8 million (Q1 2026), $95.9 million (Q4 2025), and $84.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Codexis | 180.63 Mn | 115.49 Mn | 13.18 Mn | 84.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.80 Mn |
| Dec 31, 2025 | 95.94 Mn |
| Sep 30, 2025 | 84.11 Mn |
| Jun 30, 2025 | 81.32 Mn |
| Mar 31, 2025 | 77.98 Mn |
| Dec 31, 2024 | 80.82 Mn |
| Sep 30, 2024 | 73.50 Mn |
| Jun 30, 2024 | 69.30 Mn |
| Mar 31, 2024 | 69.04 Mn |
| Dec 31, 2023 | 48.71 Mn |
| Sep 30, 2023 | 61.73 Mn |
| Jun 30, 2023 | 81.23 Mn |
| Mar 31, 2023 | 90.66 Mn |
| Dec 31, 2022 | 104.23 Mn |
| Sep 30, 2022 | 79.80 Mn |
| Jun 30, 2022 | 74.17 Mn |
| Mar 31, 2022 | 75.31 Mn |
| Dec 31, 2021 | 80.68 Mn |
| Sep 30, 2021 | 57.45 Mn |
| Jun 30, 2021 | 48.25 Mn |